Thalidomide and dexamethasone for resistant multiple myeloma

Athanasios Anagnostopoulos, Donna Weber, Kim Rankin, Kay Delasalle, Raymond Alexanian

Research output: Contribution to journalArticlepeer-review

168 Scopus citations


Between November 1998 and April 2000, the combination of thalidomide and dexamethasone was evaluated in 47 consecutive patients with multiple myeloma that was resistant to prior high-dose dexamethasone-based therapies. Remission was observed in 22 patients (47%), including six patients with complete remission. Side-effects were frequent, mild and usually reversible, but deep vein thrombosis occurred in 8% of patients. Survival and remission times were longer among patients treated for previous resistant disease rather than for resistant relapse. This experience supports the use of thalidomide-dexamethasone in myeloma patients with resistant disease and justifies further trials in newly diagnosed patients.

Original languageEnglish (US)
Pages (from-to)768-777
Number of pages10
JournalBritish Journal of Haematology
Issue number5
StatePublished - Jun 2003


  • Dexamethasone
  • Multiple myeloma
  • Thalidomide

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Thalidomide and dexamethasone for resistant multiple myeloma'. Together they form a unique fingerprint.

Cite this